Tirzepatide
FDA ApprovedAlso known as: Mounjaro, Zepbound
What is Tirzepatide?
Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist for type 2 diabetes and chronic weight management.
How It Works
Tirzepatide activates both GIP and GLP-1 receptors, providing enhanced glycemic control and weight loss compared to GLP-1 agonists alone.
What Research Shows
Key Findings:
- Up to 22.5% body weight loss in trials
- Superior A1C reduction vs semaglutide
- Improved cardiometabolic markers
Dosing Protocol
These are general guidelines based on research literature and community protocols. Individual dosing should be determined by a qualified healthcare provider.
Safety & Risks
Reported Side Effects:
Contraindications:
- Personal/family history of medullary thyroid carcinoma
- MEN 2 syndrome
- Pregnancy
Important: This information is for research purposes only. Always consult with a qualified healthcare provider before using any peptide. Never use peptides without proper medical supervision.
Sourcing & Quality
Quality varies significantly between peptide sources. When sourcing Tirzepatide, consider:
- Third-party testing (HPLC, Mass Spectrometry)
- Certificate of Analysis (CoA) availability
- Purity levels (>98% recommended)
- Beware of LPS (endotoxin) contamination
CalcPep does not sell peptides or recommend specific vendors. Always verify product quality through independent testing.
Frequently Asked Questions
Aggregated from CalcPep users who have opted in to share anonymous data.
View Full DataTrack Your Protocol
Use CalcPep to calculate doses, log injections, and track your progress.
Get CalcPep